MET - MetLife, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$101.00
DETAILS
HIGH:
$111.00
LOW:
$90.00
MEDIAN:
$103.00
CONSENSUS:
$101.00
UPSIDE:
3.97%
AlphaVal
Deterministic, archetype-aware fair value
Banks, Insurers & Asset Managers
85% confidence
Primary model: P/Tangible Book × ROE Quality
Adjust Assumptions
11.9%
8.5%
Key Value Driver
ROTCE (11.9%) vs. cost of equity (8.5%)
Implied Market Multiple
2.2x
Plain-Language Summary
With ROTCE of 11.9% vs. 8.5% cost of equity, fair P/TBV is 1.77x on $44.13 tangible book, implying $89.10 per share. DDM cross-check: $47.57.
Analyst Consensus (External Reference)
Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.
Average Target (33 analysts)
$101.00
Analyst Range
$90.00 – $111.00
Divergence from AlphaVal
12%
Warnings
Traditional cash flow models don't work well for banks — lending activity distorts how much cash the business actually generates.
Common valuation shortcuts don't apply here — for banks, interest payments are a core business cost, not overhead.
Dividend-based valuation: $47.57 (47% below our primary estimate). Large gaps suggest the dividend may not fully reflect the company's value.
Key Risks
- Book value quality matters as much as level — check loan loss reserves
- Interest rate sensitivity creates non-linear earnings surprises
- Insurance reserving is actuarial, not financial — errors emerge slowly